Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products, Opportunities and Challenges
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Antibody-Drug Conjugates Market Report Overview
An Antibody-Drug Conjugates (ADC) drug consists of monoclonal antibodies conjugated to a payload via a linker, for the precise targeting of antigen-positive cancer cells. ADCs are developed to target protein receptors with high expression such as HER2, TROP-2, CD22, and others.
There are two cytotoxic payload types predominantly used in ADCs including microtubule inhibitors, and the more potent DNA-damaging payloads such as topoisomerase I inhibitors.
The ADC market research report will aid clients in gaining insight into the competitive landscape of leading antibody-drug conjugates (ADC) in oncology. The report includes a SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players. The report also offers an outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space. Additionally, the report provides commentary on the latest trends in ADC development including payload and linker analysis.
Key Marketed Drugs | · Daiichi Sankyo’s Enhertu
· Gilead’s Trodelvy · Genmab’s Tivdak · Rakuten Medical’s Akalux |
Key Pipeline Drugs | · Ambrx Biopharma’s ARX788
· Bispecific ADC Alphamab Oncology’s JSKN003 · Daiichi Sankyo & AstraZeneca’s DS-1062 · Daiichi Sankyo’s U-31402 |
Key Players | · Daiichi Sankyo
· Pfizer · Roche · AstraZeneca · Hengrui Medicine · AbbVie |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Antibody-Drug Conjugates (ADC) – Marketed Drugs
The key marketed drugs in the ADC market are Daiichi Sankyo’s Enhertu, Gilead’s Trodelvy, Genmab’s Tivdak, and Rakuten Medical’s Akalux among others.
Daiichi Sankyo’s Enhertu: This drug is considered best-in-class ADC approved in multiple indications where HER2 is prevalent. Its key strength includes a high drug-antibody ratio with eight deruxtecan payload molecules conjugated to each trastuzumab mAb, for a higher antitumor effect. It also has higher efficacy in terms of OS and PFS versus Kadcyla in mHER2 BC.
Antibody-Drug Conjugates (ADC) Market Analysis by Marketed Drugs
Buy the Full Report for More Insights on the Key Marketed Drugs in the ADC Market
Antibody-Drug Conjugates (ADC) – Pipeline Drugs
The key pipeline drugs in the ADC market are Ambrx Biopharma’s ARX788, Bispecific ADC Alphamab Oncology’s JSKN003, Daiichi Sankyo & AstraZeneca’s DS-1062, and Daiichi Sankyo’s U-31402 among others.
Daiichi Sankyo’s Enhertu: This is a first-in-class HER3-directed deruxtecan ADC product. The ADC received breakthrough designation and priority review of its BLA from the FDA for 3L+ EGFR mutated NSCLC.
Antibody-Drug Conjugates (ADC) Market Analysis by Pipeline Drugs
Buy the Full Report for More Insights on the Key Pipeline Drugs in the ADC Market
Antibody-Drug Conjugates (ADC) – Competitive Landscape
The key players in the ADC market are Daiichi Sankyo, Pfizer, Roche, AstraZeneca, Hengrui Medicine, and AbbVie among others.
Daiichi Sankyo Co Ltd: Daiichi Sankyo is headquartered in Tokyo, Japan. It is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over-the-counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia.
Antibody-Drug Conjugates (ADC) Market Analysis by Players
Buy the Full Report for More Insights on the Key ADC Players
Scope
- Clients will gain insight into the competitive landscape of leading antibody-drug conjugates (ADC) through this report.
- The report includes a SWOT analysis for key marketed and pipeline drugs, clinical benchmark comparisons, key clinical trial analysis, analyst consensus forecasts, and commentary on current and future players.
- The report offers an outlook from four key opinion leaders in the US and analyzes key opportunities and challenges in the space.
- The report provides commentary on the latest trends in ADC development including payload and linker analysis.
Reasons to Buy
Our modality-specific reports answer questions such as –
- What is the future global market value of ADCs in Oncology?
- Which cancer types are more likely to receive these therapies?
- What are the clinical benchmarks for currently approved ADCs?
- What are the emergent linkers and payloads for ADCs?
- What is the key opinion leaders’ outlook for the products?
- What are key opportunities and challenges in the area?
Frequently asked questions
-
Which are the key marketed drugs in the ADC market?
The key marketed drugs in the ADC market are Daiichi Sankyo’s Enhertu, Gilead’s Trodelvy, Genmab’s Tivdak, and Rakuten Medical’s Akalux among others.
-
Which are the key pipeline drugs in the ADC market?
The key pipeline drugs in the ADC market are Ambrx Biopharma’s ARX788, Bispecific ADC Alphamab Oncology’s JSKN003, Daiichi Sankyo & AstraZeneca’s DS-1062, and Daiichi Sankyo’s U-31402 among others.
-
Which are the key players in the ADC market?
The key players in the ADC market are Daiichi Sankyo, Pfizer, Roche, AstraZeneca, Hengrui Medicine, and AbbVie among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.